GlassScriptPhysician profile
Bruno Romeo
NPI 1689615247
$10,516.31
in general payments reported to CMS, 2019-2025
36 companies · $205 in 2025
The $205 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,695 · 2020: $1,194 · 2021: $1,134 · 2022: $1,987 · 2023: $2,363 · 2024: $1,938 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,234 · Education: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,233.77 |
| Education | $272.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,177.45 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,689.89 | 2019-2025 | Airsupra, Tezspire, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $915.20 | 2019-2024 | Ofev |
| Actelion Pharmaceuticals US, INC. | $677.70 | 2022-2024 | Uptravi, Opsumit |
| Takeda Pharmaceuticals U.S.A., INC. | $465.67 | 2020-2024 | Glassia |
| Amgen INC. | $464.12 | 2019-2024 | Tezspire |
| Genzyme Corporation | $396.99 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $301.43 | 2022-2024 | Dupixent |
| Harmony Biosciences LLC | $286.64 | 2020-2024 | Wakix |
| Janssen Pharmaceuticals, INC | $278.00 | 2019-2021 | |
| Pfizer INC. | $275.73 | 2019-2024 | |
| Philips North America LLC | $216.43 | 2020-2024 | (Ak6) Vest Therapy |
| Novartis Pharmaceuticals Corporation | $211.34 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $120.55 | 2019-2024 | Camzyos |
| Verona Pharma, INC. | $103.40 | 2025 | Ohtuvayre |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $101.22 | 2019-2021 | |
| Amarin Pharma, INC. | $99.12 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $88.93 | 2020-2024 | Dificid |
| Mylan Specialty L.P. | $79.38 | 2022-2024 | Yupelri |
| Grifols USA, LLC | $70.33 | 2019-2021 | |
| Biofire Diagnostics, LLC | $59.91 | 2020 | |
| Baxter Healthcare | $55.36 | 2022-2023 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| United Therapeutics Corporation | $54.88 | 2021-2023 | Tyvaso |
| Astellas Pharma US INC | $45.68 | 2019 | |
| Vifor Pharma, INC. | $30.87 | 2024 | Zemaira |
| Paratek Pharmaceuticals, INC. | $27.98 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $27.62 | 2019 | |
| Resmed Corp | $27.60 | 2024 | |
| Janssen Biotech, INC. | $26.37 | 2023 | |
| Sunovion Pharmaceuticals INC. | $24.95 | 2019 | |
| Allergan, INC. | $23.20 | 2020 | |
| Electromed, INC. | $22.42 | 2022 | |
| Insmed, INC. | $22.05 | 2024 | Arikayce |
| Inspire Medical Systems, INC. | $20.48 | 2024 | Inspire |
| Jazz Pharmaceuticals INC. | $14.42 | 2019 | |
| Sanofi Pasteur INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruno Romeo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.